Skip to search formSkip to main contentSkip to account menu

CI 1040

Known as: CI-1040, CI1040 
National Institutes of Health

Related topics

Related topics

1 relation
PD 184352

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Mechanisms of Acquired Resistance to Venetoclax in Preclinical AML Models
BH3-mimetic ABT-199 (venetoclax, VEN) is a selective small-molecule antagonist of the anti-apoptotic BCL-2 protein. It binds to… 
2013
2013
Combination of Rapamycin, CI-1040, and 17-AAG Inhibits Metastatic Capacity of Prostate Cancer via Slug Inhibition
Though prostate cancer (PCa) has slow progression, the hormone refractory (HRCP) and metastatic entities are substantially lethal… 
2012
2012
Abstract 3: HER2 gene-amplified human breast cancer cells harboring a gatekeeper T768M mutation in HER2 overexpress EGFR ligands and are sensitive to dual therapeutic blockade of EGFR and HER2
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Intrinsic or acquired mutations in receptor… 
2012
2012
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo
Activating mutations in Kras are the most frequent mutations in human cancer. They define a subset of patients who do not respond… 
2010
2010
MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2.
The extracellular-regulated kinase (ERK) signaling pathway plays an important role in regulating the malignant potential of a… 
2010
2010
Abstract 3494: Experimentally validated modeling for optimizing therapeutic combinations of oncolytic adenoviruses and MEK inhibitor
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Oncolytic adenoviruses are therapeutic anti-cancer… 
2008
2008
Pros and cons of cellular studies in developing new drugs for thyroid cancers.
2006
2006
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration
One specific limitation to the clinical development of targeted cancer therapeutics is the lack of well-validated pharmacodynamic… 
2005
2005
Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells.
Conditionally active forms of the Raf proteins (Raf-1, B-Raf, and A-Raf) were created by ligating NH2-terminal truncated… 
2003
2003
Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.
1. Peddie CM, Wolf CR, Mclellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)